LAS VEGAS, Oct. 19, 2015 (GLOBE NEWSWIRE) — (VRCI) Verde Science, Inc., is a leading Pharmaceutical Research and Development Company that maintains a strong collaboration with leading scientists and pharma companies to create and test pharmaceutical formulations for optimal dosage and delivery mechanisms. Verde Science is pleased to announce that a renown doctor has joined Verde Science as a consultant to lead the research team for the study of a cannabis preparation in the treatment of Huntingtons Disease.

The doctor is a distinguished researcher in the field of Neurotoxicology and Parkinsons Disease. He is Professor in the Department of Neurology and the Department of Molecular Pharmacology and Physiology, and is the Vice Chair for Research for the Department.

He graduated with his PhD and has since been involved in cutting edge studies and has been a prolific publisher of research in medical journals over the last many years. The doctor has been involved in many neurotoxicology studies of various narcotic derivatives and is a lead researcher in the field of Parkinsons Disease in the U.S. He holds numerous patents for devices and delivery systems for treatment and cellular repair. He has personally consulted for a large number of projects, foundations and companies including Elan Pharma, SmithKline Beecham and Lundbeck Inc.

The doctor has previous experience in clinical studies of Huntington’s Disease as well as the effects of Cannabinoids for the treatment of movement disorders. He will be leading the Verde research team and will be attending this year’s Huntington Study Group Conference at the Grand Hyatt, Tampa Bay, FL.

Harp Sangha, CEO of Verde Science commented, “We are pleased to have the reknown doctor consult with us for this important field of research. We truly cannot overstate how his experience with directing, managing and participating in clinical studies will greatly benefit the effectiveness of the planned study.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

LAS VEGAS, NV / ACCESSWIRE / October 12, 2015 / (OTCQB:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabis-based prescription medicines to meet patients’ needs for a wide range of medical conditions, is pleased to announce it will be sponsoring and presenting at the twenty-third annual Huntington Study Group Conference (http://huntingtonstudygroup.org/) This year’s conference, HSG 2015: Building Our Future is being held from October 21-24, 2015 at the Grand Hyatt, Tampa Bay, FL.

Harp Sangha, CEO of Verde Science commented, “We are honored to sponsor this important conference and to do our part to improve the outcomes and lives of people who suffer this condition”.

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

LAS VEGAS, Oct. 9, 2015 (Globe Newswire) – Verde Science, Inc. (VRCI), a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients’ needs for a wide range of medical conditions, is pleased to announce that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon’s Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.

Harp Sangha, CEO of Verde Science commented, “We will be embarking on our first research study into the potential of cannabis preparations to treat medical conditions and improve lives. Our team is excited to approach this milestone and is hopeful that it will lead to an efficacious and commercially viable pharmaceutical product and additional research studies for treating other medical conditions.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / May 20, 2015 / (VRCI-OTCQB) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.

Mr. Schauer is a seasoned international banker, entrepreneur and investor with over four decades of business experience. He was educated in Germany, followed by a 15 year career with Deutsche Bank. Based in Hong Kong as Regional Treasurer he was responsible for asset and liability and risk management, and all money market and foreign exchange trading operations for Deutsche Banks Asia Pacific subsidiary network in 13 countries. He built up similar regional treasury capabilities for Amsterdam-Rotterdam Bank and Continental Illinois National Bank based in Hong Kong and Japan for another 5 years. From New Zealand Mr. Schauer now runs his own independent consulting business. This involves a wide range of international projects from corporate finance and early stage funding, to mergers and acquisitions and general corporate and management advisory services. Over the last dozen years he has been involved in a number of companies in the USA and Canada.

Mr. Schauer commented, I am excited of being part of the new Verde Science team. The company has an excellent opportunity to grow quickly and attain a strong position in the burgeoning medical marijuana pharma sector. I look forward to committing my expertise and experience in order to play my part in building Verde Science into a substantial and successful company.

Mr. Harp Sangha, Verdes CEO offered, Manfred Schauer is an important addition to the Verde team. His international banking and finance network and his vast experience and business acumen compliments and strengthens our ability to successfully execute the Verde business plan.

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / May 20, 2015 / (VRCI-OTCQB) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing effective treatments for contemporary health issues, with an initial focus on developing cannabinoid-based prescription medicines is pleased to announce the appointment of Bradley J. Dixon, J.D. to its Board of Directors. Mr. Dixon is a partner with the firm of Stoel Rives, LLP, which has offices throughout the Northwest and California. His professional honors include selection as one of America’s Leading Lawyers for Business by Chambers USA, listing in Mountain States Super Lawyers, and admission to the Order of Barristers. Mr. Dixon’s areas of practice include Business Law, Government Affairs, Commercial Litigation, and Labor and Employment Law.

Verde Science CEO, Harp Sangha commented, “As Verde Science accelerates its development into a more complex international structure with multiple interconnected facets including research and product development, intellectual property, and corporate finance and governance, it has become apparent that participation from legal professionals is a required input for our strategic and tactical decision-making. I am proud and excited to have Brad add his experience in this regard and to be able to benefit from his business and legal acumen.”

“Harp Sangha has assembled a world-class research and development team that seems poised to achieve an eminent position in the medical marijuana field. I am an energetic supporter of their pharmacological approach that avoids numerous regulatory and legal pitfalls. I am honored to be a part of this company,” according to Bradley Dixon.

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / May 12, 2015 / (VRCI-OTCQB) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients’ needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq: CRME).

According to David, “Verde Science possesses several elements for success in the pharmaceutical research, development and commercialization arena. I am pleased to be part of the team that Harp has assembled and to assist in financing and managing the significant growth that the company envisions.”

CEO, Harp Sangha commented, “I am delighted to have David join Verde Science at this time in our development. He is exactly what Verde Science needs – a growth oriented CFO. His success in managing and accelerating the growth of early stage companies, specifically in the pharmaceutical sector should prove to be invaluable.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Harp Sangha, Chairman
Tel:        1-604-825-1309
Email:   hsangha@verdescienceinc.com
Facebook:  goo.gl/gxQFZz

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / May 4, 2015 (VRCI-OTCQB) Verde Science, Inc. a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions is pleased to announce the appointment of John M. E. Percival to its Board of Directors and Head of Strategic Business Development. Mr. Percival brings over 20 years of Investment Banking, Corporate Finance and Strategic planning success to Verde. Mr. Percival was previously General Manager of Investments at Barclays Bank New Zealand Ltd., where he was responsible for the management of nearly a $500 million in superannuation and private funds.

Mr. Percival commented, “I am extremely excited to be asked to join the Board of Directors of Verde Science. My assessment of the nascent medical marijuana space convinces me of the attractiveness of the Verde Science pharmacological approach to harness the healing powers of the medical marijuana plant and aid the company in its pathway to bring medicine to market. I look forward to being an active participant in the growth of Verde and the attainment of its goals for the improvement of health care treatment throughout the world and particularly in Australia where the Queensland Government has recently announced a significant program to research the benefits of medical marijuana.”

Verde Science CEO, Harp Sangha offered, “I am delighted with the addition of John Percival. John brings a pristine record of success and I believe he will be a highly effective resource and rainmaker for the company.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB)  is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Louis Silver
Tel: 1-610-710-1303
lsilver@verdescienceinc.com

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / April 10, 2015 / (VRCI-OTCQB) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the addition of Shantesh Hede, Ph.D. as Director of Product Development. Dr. Hede will be based in Mumbai, India and will direct Verde Science’s R&D programs on-site with Verde’s Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelors in Pharmaceutical Sciences from the Institute of Chemical Technology.

Dr. Hede stated, “Verde Science is uniquely positioned to leverage its R&D platform alliances with existing partners in healthcare institutions, academia and the pharmaceutical industry for the identification and commercialization of specific formulations derived from the marijuana plant for the treatment of numerous medical conditions. I look forward to being a part of this exciting effort and focusing Verde’s scientific activities on applications that will produce significant intellectual property in areas of limited market competition to produce substantial value for our shareholders.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Louis Silver
Tel: 1-610-710-1303
lsilver@verdescienceinc.com

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / April 8, 2015 / (VRCI-OTCQB) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the execution of a definitive Research and Development Agreement with the Institute of Chemical Technology of Mumbai, India. Under the terms of the agreement Verde Science researchers and faculty and staff of the University will cooperate on original research with the goal of identifying and developing novel pharmaceutical formulations derived from the marijuana plant for the treatment of specific medical issues.

The Institute of Chemical Technology (ICT), established in 1933 was granted “deemed University status” in 2008 and offers undergraduate, masters, and Ph.D. degree programs in various Chemical Engineering disciplines including the Technology of Pharmaceutical and Fine Chemicals. ICT awards approximately 100 Ph.D. degrees annually.

“This relationship is a significant development for Verde and ICT that will fast track the startup of our initial R&D projects in conjunction with ICT’s prestigious faculty and within ICT’s scientific infrastructure. Our initial projects will focus on the development of efficacious formulations with specific application to the treatment of seizures and pain management, administered with the use of novel delivery systems. Further, this marks our initial step toward becoming a leader in scientific research for the development of advanced formulations of cannabis-based compounds for medical use,” according to Harp Sangha, CEO of Verde Science.

Louis Silver, Verde Science Director of Investor Relations, added, “Many in the medical community have conceded the effectiveness of medical marijuana for the treatment of certain medical issues. However, virtually every credible medical organization has stated that smoking marijuana is deleterious to health. The Verde Science pharmacological model mitigates the risks inherent in the traditional use of marijuana by isolating active ingredients in the marijuana plant and delivering them in safe, medically acceptable forms.”

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

Information
For further information please see our investor profile available on our website: www.verdescienceinc.com.

Contact
Louis Silver
Tel: 1-610-710-1303
lsilver@verdescienceinc.com

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Las Vegas NV / March 13, 2015 / Verde Science, Inc., (VRCI-OTCQB) a Medical Research and Development Company focused on developing effective treatments for emerging and contemporary health issues, with an initial focus on Medical Marijuana is pleased to update shareholders and investors regarding significant developments in the Medical Marijuana R&D arena.

Verde Science has firmly established its Research and Development platform with research scientists, project directors, and research institutions based in India, Canada and the U.S.; has identified several initial promising R&D projects; and completed its consolidated R&D and business plan. “Achieving these critical steps clears the path for Verde to embark on the development of specific pharmaceutical formulations based on the marijuana plant, and enhances our ability to compete effectively in the burgeoning Medical Marijuana field,” according to Harp Sangha, Verde Science CEO.

“This is an especially timely development, as a landmark bi-partison Medical Marijuana bill called the Compassionate Access, Research Expansion and Respect States (CARERS) Act was introduced in the U.S. Senate on March 10th. The bill would remove federal penalties and restrictions for producing, distributing and possessing marijuana for medical purposes. More important for Verde Science is that the bill would eliminate current barriers to research and development and recognize the acceptable medical use of marijuana,” according to Louis Silver Verde Science Director of Investor Relations. Among the bill’s sponsors are Senators Rand Paul, Republican of Kentucky and Cory Booker, Democrat of New Jersey.

Also, on Sunday, March 15th, 2015 at 8:30 pm EST Paul Pelosi Jr. who is on VRCI’s Advisory Board, and Louis Silver Managing Director of Investor Relations, will be appearing on the popular internet radio show, Pot Stock radio, at http://potstockradio.com/pot-stock-radio-verde-science-force-fuels-wolf-weed-st-alan-brochstein/.

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (www.VerdeScienceInc.com) is a public company trading under the symbol (VRCI-OTCQB). The Company is focused on Medical Marijuana Research and Development, and providing advisory services, quality assurance, and aeroponic growing systems in the burgeoning Medical Marijuana industry to established, licensed growers throughout Canada.

For further information please contact:
Harp Sangha, Chairman/CEO
Tel: 1-604-825-1309
hsangha@verdescienceinc.com

Louis Silver
Tel: 1-610-710-1303
lsilver@verdescienceinc.com

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.